●厲勇 葉海霞 張建新
促紅細(xì)胞生成素皮下注射對(duì)跟腱損傷愈合影響的機(jī)制研究
●厲勇 葉海霞 張建新
目的:促紅細(xì)胞生成素(Erythropoietin,EPO)具有促進(jìn)損傷組織修復(fù)作用。通過(guò)觀察EPO局部注射對(duì)大白兔跟腱斷裂早期愈合的影響,為臨床應(yīng)用提供實(shí)驗(yàn)依據(jù)。方法:36只新西蘭大白兔隨機(jī)分成2組,分別為對(duì)照組和實(shí)驗(yàn)組各18只。取右后下肢跟腱附著點(diǎn)上方2cm左右,切斷跟腱建立跟腱損傷模型,采用改良kessler法縫合跟腱斷端,縫合處放置生物降解膜包裹,皮膚縫合后石膏固定右側(cè)下肢為跖屈位。術(shù)后實(shí)驗(yàn)組右后肢皮下注射重組促紅細(xì)胞生成素,對(duì)照組則注射同等容量的生理鹽水,時(shí)間均為7天,1/日。術(shù)后各組分批次2周、4周、6周處死新西蘭大白兔(4只、4只、10只),分別對(duì)跟腱周圍組織進(jìn)行粘連分級(jí),各時(shí)間段各取4只跟腱斷端進(jìn)行組織病理學(xué)檢測(cè)(H&E染色,Masson染色,免疫組化分析),統(tǒng)計(jì)學(xué)分析組織的成纖維細(xì)胞數(shù)目、膠原纖維含量。對(duì)余下兩組各6只標(biāo)本進(jìn)行肌腱的生物力學(xué)拉力測(cè)試并統(tǒng)計(jì)學(xué)分析。結(jié)果:大白兔均存活至實(shí)驗(yàn)完成。隨著時(shí)間延長(zhǎng),各組大白兔跟腱水腫逐漸減退,滑動(dòng)性逐漸改善;術(shù)后3周內(nèi)各組跟腱粘連逐漸加重,4周時(shí)減輕,1、4周時(shí)各組跟腱粘連程度分級(jí)差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。術(shù)后1周EPO組炎性細(xì)胞浸潤(rùn)、毛細(xì)血管及膠原纖維增殖較空白對(duì)照組、PPP組明顯,之后炎性反應(yīng)及毛細(xì)血管生成逐漸減少。各時(shí)間點(diǎn)各組均可見Ⅰ型膠原纖維陽(yáng)性表達(dá),術(shù)后1、2、3周EPO 組Ⅰ型膠原纖維陽(yáng)性密度值多于空白對(duì)照組和PPP組(P<0.05),4周時(shí)3組差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。生物力學(xué)測(cè)試:術(shù)后4周3組跟腱最大滑動(dòng)距離比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);EPO 組跟腱彈性模量及最大抗拉力明顯高于空白對(duì)照組及PPP組(P<0.05)。結(jié)論:大白兔跟腱斷裂早期于斷端周圍注射EPO能促進(jìn)跟腱愈合。
促紅細(xì)胞生成素;跟腱斷裂;跟腱愈合Ⅰ型膠原;新西蘭大白兔
促紅細(xì)胞生成素(EPO)是主要由腎臟分泌的一種特異性糖蛋白類激素,結(jié)構(gòu)中含有的特異性糖鏈結(jié)構(gòu)能夠與骨髓紅細(xì)胞表面特異的識(shí)別受體相結(jié)合,能促進(jìn)骨髓紅細(xì)胞的增值與成熟,對(duì)機(jī)體血氧的供應(yīng)狀況發(fā)揮重要的調(diào)控作用。EPO最初是用來(lái)治療癌癥、慢性腎衰以及其他的一些疾病引起的貧血癥,隨著對(duì)促紅細(xì)胞生成素在神經(jīng)系統(tǒng)、運(yùn)動(dòng)系統(tǒng)以及血管壁修復(fù)、心肌疾病等方面的信號(hào)傳導(dǎo)和作用機(jī)制的進(jìn)一步深入研究,發(fā)現(xiàn)EPO還有一些非造血生物學(xué)的作用。例如抗細(xì)胞凋亡、抗氧化、抗炎、促進(jìn)血管增生生長(zhǎng)的作用,而且對(duì)平滑肌細(xì)胞、內(nèi)皮細(xì)胞、骨骼肌成纖維細(xì)胞、神經(jīng)元細(xì)胞等多種細(xì)胞均有表達(dá)。EPO能夠刺激和促進(jìn)骨髓紅細(xì)胞的增值和成熟,能夠增強(qiáng)機(jī)體肌肉組織對(duì)氧的結(jié)合、運(yùn)輸和供應(yīng)能力,促進(jìn)肌肉中氧生成,改善了機(jī)體的缺氧狀態(tài),從而使肌肉更加有力、工作時(shí)間更長(zhǎng)。骨骼肌主要是靠有氧代謝方式供給能量,供氧能力可以直接影響骨骼肌的工作效率,因此EPO的應(yīng)用可以提高血紅蛋白的攜氧能力,從而提高骨骼肌的工作效率。近年的國(guó)外有實(shí)驗(yàn)證明EPO在多種臟器如腎臟,腸道,和骨骼肌能夠誘導(dǎo)細(xì)胞的增殖,促進(jìn)毛細(xì)血管的增生,還能提高早期的軟骨鈣化和骨折愈合,能夠增強(qiáng)骨骼的機(jī)械強(qiáng)度。由于促紅細(xì)胞生成素具有這些抗凋亡、保護(hù)再生、促進(jìn)血管生長(zhǎng)的作用,伴隨著隨著臨床基礎(chǔ)研究的更進(jìn)一步的深入,EPO的應(yīng)用會(huì)更加廣泛。
(1)生物力學(xué)檢測(cè):采用BOSE ElectroForce 3510高精度生物材料試驗(yàn)系統(tǒng)(美國(guó)),比較各實(shí)驗(yàn)組標(biāo)本力學(xué)指標(biāo)。術(shù)后第6周末切取新西蘭兔右側(cè)下肢盡量完整的跟腱,0.9%NaCl溶液紗布包裹,冰柜冰凍保存。拉力測(cè)試前攝氏20度自然解凍。新西蘭兔跟腱標(biāo)本進(jìn)行最大生物拉力(速度設(shè)定在20mm/min)測(cè)試,直至肌腱斷裂所示的拉力數(shù)值,為肌腱最大抗拉力值。
(2)跟腱標(biāo)本粘連度評(píng)分:采用Hitchcock粘連分級(jí)量表對(duì)各標(biāo)本進(jìn)行評(píng)分。
(3)H&E染色觀察:統(tǒng)計(jì)成纖維細(xì)胞以及炎性細(xì)胞計(jì)數(shù)。
(4)Masson三色染色觀察:對(duì)比纖維形態(tài)。Masson三色染色后,顯微鏡下觀察,肌腱正常膠原纖維染成藍(lán)色,整齊排列,肌纖維、神經(jīng)膠質(zhì)呈紅色,胞核黑藍(lán)色。
(5)免疫組化分析:對(duì)比每組標(biāo)本VEGF,Collegen-1,Collegen-2,CD31, RANKL,OPG的表達(dá)情況。
(6)所有數(shù)據(jù)資料均采用SPSSl7.0統(tǒng)計(jì)軟件進(jìn)行分析與處理。定量資料若符合正態(tài)分布、方差齊性則進(jìn)行T檢驗(yàn),用均數(shù)±標(biāo)準(zhǔn)差(s)表示;定性資料采用秩和檢驗(yàn),a=0.05;2周、4周、6周兩組采用單因素方差分析進(jìn)行各組組內(nèi)縱向比較。
各組大白兔均存活至實(shí)驗(yàn)完成。大白兔切口均愈合良好;術(shù)后1~2d精神差,活動(dòng)少,3d時(shí)行走跛行,1周后恢復(fù)正常行走。
術(shù)后1周,各組跟腱及腱周組織發(fā)生水腫,與其周圍組織輕度粘連,跟腱兩斷端見少量新生纖維組織,與周圍疏松組織界限不清。2周時(shí),各組跟腱及其周圍組織水腫較前減退,粘連較1周時(shí)無(wú)明顯變化,兩斷端由纖維組織連接,滑動(dòng)性差。3周時(shí),各組跟腱無(wú)明顯水腫,粘連范圍較前增加,但易分開,無(wú)明顯滑動(dòng)性。4周時(shí),跟腱與周圍組織粘連較3周時(shí)明顯減輕,與1、2周時(shí)跟腱粘連無(wú)明顯差異,跟腱滑動(dòng)性明顯改善,跟腱比1周時(shí)增粗;空白對(duì)照組跟腱粘連最嚴(yán)重。術(shù)后1、4周時(shí)各組跟腱粘連程度分級(jí)比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。
術(shù)后1周,鏡下見各組膠原纖維排列疏松、散裂,組織間水腫,炎性細(xì)胞浸潤(rùn);可見膠原纖維增殖,組織間有新生毛細(xì)血管,EPO組膠原纖維增殖及新生血管均優(yōu)于其他兩組(圖1)。2、3周時(shí),各組組織水腫較1周時(shí)減輕,炎性細(xì)胞減少,仍可見排列紊亂的膠原纖維組織,膠原組織間毛細(xì)血管較1周時(shí)減少。4周時(shí),各組組織間水腫消退,跟腱炎性反應(yīng)基本消退,但空白對(duì)照組仍可見少量炎性細(xì)胞;膠原纖維排列較前整齊,各組毛細(xì)血管較1周時(shí)減少;與空白對(duì)照組及PPP組比較,EPO組膠原纖維排列致密,膠原纖維細(xì)胞數(shù)減少,細(xì)胞呈細(xì)長(zhǎng)形,核變小,排列規(guī)律;PPP 組細(xì)胞核深染,膠原纖維可見褶皺,走行不平整(圖2)。
術(shù)后各時(shí)間點(diǎn)各組均可見陽(yáng)性染色,其中1~3周時(shí)EPO組陽(yáng)性染色纖維多于空白對(duì)照組和PPP組(圖3),4周時(shí)3組無(wú)顯著差異(圖4)。術(shù)后1、2、3周,EPO組Ⅰ型膠原纖維陽(yáng)性密度值均高于空白對(duì)照組及PPP組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);除1周時(shí)PPP組與空白對(duì)照組間差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)外,2、3周時(shí)PPP組均高于空白對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。術(shù)后4周3組Ⅰ型膠原纖維陽(yáng)性密度值比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。
術(shù)后4周EPO組跟腱彈性模量及最大抗拉力明顯高于空白對(duì)照組及PPP組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),空白對(duì)照組和PPP組間差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。3組跟腱最大滑動(dòng)距離比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。
跟腱損傷是運(yùn)動(dòng)系統(tǒng)的最常見疾病之一,隨著人群對(duì)健康的越來(lái)越重視,導(dǎo)致發(fā)病率逐步上升。由于跟腱中段血液循環(huán)較差和跟骨結(jié)節(jié)上方2-6cm最為薄弱這些特殊的解剖生理學(xué)特點(diǎn),損傷后的跟腱修復(fù)極為不易[1-3]。醫(yī)務(wù)工作者臨床上盡力保持跟腱腱鞘的的連續(xù)性和平整光滑,但術(shù)后功能的恢復(fù)欠佳。多年來(lái)人們通過(guò)大量的實(shí)驗(yàn)研究,探索出了許多促進(jìn)肌腱愈合的方法[4]。隨著分子生物學(xué)的發(fā)展和研究,文獻(xiàn)顯示有很多細(xì)胞生長(zhǎng)因子及藥物在肌腱愈合過(guò)程中發(fā)揮著重要的作用,它們?cè)诩‰煊系牟煌A段調(diào)控細(xì)胞的增值、基質(zhì)膠原合成[5-7]。
促紅細(xì)胞生成素(EPO)是主要由腎臟分泌的一種特異性糖蛋白類激素,結(jié)構(gòu)中含有的特異性糖鏈結(jié)構(gòu)能夠與骨髓紅細(xì)胞表面特異的識(shí)別受體相結(jié)合,能促進(jìn)骨髓紅細(xì)胞的增值與成熟,對(duì)機(jī)體血氧的供應(yīng)狀況發(fā)揮重要的調(diào)控作用。EPO最初是用來(lái)治療癌癥、慢性腎衰以及其他的一些疾病引起的貧血癥[8-10],隨著對(duì)促紅細(xì)胞生成素在神經(jīng)系統(tǒng)、運(yùn)動(dòng)系統(tǒng)以及血管壁修復(fù)、心肌疾病等方面的信號(hào)傳導(dǎo)和作用機(jī)制的進(jìn)一步深入研究,發(fā)現(xiàn)EPO還有一些非造血生物學(xué)的作用。例如抗細(xì)胞凋亡、抗氧化、抗炎、促進(jìn)血管增生生長(zhǎng)的作用,而且對(duì)平滑肌細(xì)胞、內(nèi)皮細(xì)胞、骨骼肌成纖維細(xì)胞、神經(jīng)元細(xì)胞等多種細(xì)胞均有表達(dá)。EPO能夠刺激和促進(jìn)骨髓紅細(xì)胞的增值和成熟,能夠增強(qiáng)機(jī)體肌肉組織對(duì)氧的結(jié)合、運(yùn)輸和供應(yīng)能力,促進(jìn)肌肉中氧生成,改善了機(jī)體的缺氧狀態(tài),從而使肌肉更加有力、工作時(shí)間更長(zhǎng)。骨骼肌主要是靠有氧代謝方式供給能量,供氧能力可以直接影響骨骼肌的工作效率,因此EPO的應(yīng)用可以提高血紅蛋白的攜氧能力,從而提高骨骼肌的工作效率。近年的國(guó)外有實(shí)驗(yàn)證明EPO在多種臟器如腎臟,腸道,和骨骼肌能夠誘導(dǎo)細(xì)胞的增殖,促進(jìn)毛細(xì)血管的增生,還能提高早期的軟骨鈣化和骨折愈合,能夠增強(qiáng)骨骼的機(jī)械強(qiáng)度[11-13]。由于促紅細(xì)胞生成素具有這些抗凋亡、保護(hù)再生、促進(jìn)血管生長(zhǎng)的作用,伴隨著隨著臨床基礎(chǔ)研究的更進(jìn)一步的深入,EPO的應(yīng)用會(huì)更加廣泛[14-16]。
目前在肌腱損傷修復(fù)愈合的過(guò)程中對(duì)成纖維細(xì)胞生長(zhǎng)因子(bFGF)及血管內(nèi)皮生長(zhǎng)因子(vEGF)等多種生長(zhǎng)因子的作用研究較多,也取得了不錯(cuò)的結(jié)果。體內(nèi)外實(shí)驗(yàn)均表明這些生長(zhǎng)因子在肌腱愈合中起著積極的作用,但對(duì)EPO在肌腱愈合中的作用未見有試驗(yàn)研究,此藥物在肌腱愈合的過(guò)程中是如何發(fā)揮作用的都還需要進(jìn)行實(shí)驗(yàn)研究。本課題實(shí)驗(yàn)將重組促紅細(xì)胞生成素(rllEPO)應(yīng)用于損傷的跟腱,檢測(cè)其對(duì)跟腱內(nèi)源性愈合的作用,并進(jìn)行試驗(yàn)對(duì)比。希望通過(guò)本實(shí)驗(yàn)了解rhEPO是否起著促進(jìn)肌腱的內(nèi)源性愈合的作用,或者在肌腱愈合的不同階段,作用會(huì)有什么變化,探討其對(duì)肌腱愈合的作用,為進(jìn)一步研究生長(zhǎng)因子及將來(lái)更好地將次藥物應(yīng)用于臨床提供動(dòng)物實(shí)驗(yàn)及理論依據(jù)。
本研究組織學(xué)觀察結(jié)果表明,術(shù)后1周EPO組跟腱實(shí)質(zhì)內(nèi)新生血管較其他兩組增多、炎性細(xì)胞少,成纖維細(xì)胞增殖、膠原分泌以及膠原纖維數(shù)量亦較多。盛加根等[20]研究發(fā)現(xiàn),在肌腱愈合初期于肌腱斷端使用外源性bFGF能改善肌腱實(shí)質(zhì)內(nèi)bFGF低水平狀態(tài),促進(jìn)細(xì)胞增殖及刺激肌腱內(nèi)血管的生成。EPO中因含有各種生長(zhǎng)因子綜合作用有關(guān),一方面刺激了瘢痕組織生成,另一方面促進(jìn)血管生成有利于損傷組織修復(fù),從而減少了瘢痕組織形成。Taylor等[23]的系統(tǒng)評(píng)價(jià)認(rèn)為EPO能促進(jìn)運(yùn)動(dòng)引起的肌腱和韌帶損傷恢復(fù),但只納入了3篇研究。Schepull等[24]的一項(xiàng)臨床隨機(jī)對(duì)照研究認(rèn)為EPO對(duì)促進(jìn)跟腱斷裂的愈合無(wú)明顯作用,該研究中的指標(biāo)測(cè)量時(shí)間分別為術(shù)后7、19、52周。本研究結(jié)果表明,在跟腱斷裂后1周EPO能明顯促進(jìn)跟腱愈合,4周時(shí)則無(wú)此表現(xiàn)。因此,根據(jù)以往文獻(xiàn)研究及本研究結(jié)果,我們認(rèn)為PRP在跟腱愈合早期(<4周)可能具有促進(jìn)跟腱愈合作用,EPO在跟腱斷裂4周以后的相關(guān)作用還有待進(jìn)一步研究。
(作者單位:浙江省青田縣人民醫(yī)院骨科)
[1]Boyer MI,Goldfarb CA,Gelberman RH.Reeent progress in flexor tendon healing.Themodulation oftendon healing with rehabilitation variables[J].J Hand Ther,2005,1 8(2):80.
[2]Tang JB,Xu YDing Let a1.Expression of genes for collagen preduction and NF-kappa Bgene activation of in vivo healing flexor tendons[J].J Hand Surg,2004,29(4):564.
[3]Daniel K.Lee,DPM,F(xiàn)ACFASAchilles,Tendon Repair with Acellular Tissue GraftAugmentation in Neglected Ruptures,[J].THE JOURNAL OF FOOT&ANKLESUtGERY,VOLUME 46,NUMBER 6,NOVEMBER/DECEMBER2007.
[4]王愛民.促進(jìn)肌腱愈合的研究進(jìn)展[J].中國(guó)矯形外科雜志,1996,3(4):218.
[5]Klein M B,Yalamanchi N,Pham H,Longaker M T,Chang J.Flexor tendon healing inritro:effects ofTGF·13 on tendon cell collagen production.H Hand Surg 2002,27A:615—620.
[6]Yoshikawa Y,Abrahamsson SO.Dose-related cellular effects of platelect-derived growthfactor-BB differ in various types of rabbit tendons in vitro.Acta Orthop Scand2001,72:287—292.
[7]Abrahamsson SO,Lundborg G,Lohmander LS.Long-term explant culture of rabbit flexortendon:effects of recombinant human insulin-like growth factor-1 and serum on matrixmetabolism.J Orthop Res 1991,9:503-5 1 5.
[8]Reissmann KR.1 950.Studies on the mechanism of erythropoietic stimulation inparabiotic rats during hypoxia.Blood5:372—380.
[9]Erslev A.1953.Humoral regulation ofred cell production.Blood 8:349—357.
[10]Jelkmann W.2007.Erythropoietin after a century of research:younger than ever.Eur JHaematol 78:1 83—205.
[11]Ogilvie,M.,Yu,X.,Nicolas-Metral,V,Pulido,S.M.,Liu,C.,Ruegg,U.T.,Noguchi,C.T.,2000.Erythropoietin stimulates proliferation and interferes with differentiation ofmyoblasts.Journal ofBiological Chemistry 275(50),39754—39761.
[12]Juul,S.E.,Ledbeaer’D.J.,Joyce,A.E.,Dame,C.,Christensen,R.D.,Zhao,Y,DeMarco,V,200 1.Erythropoietin acts as a trophic factor in neonatal rat intestine.Gut 49(2),1 82—189.
[13]Joerg H.Holstein etal.Erythropoietin(EPO)—EPO—receptor signaling improves earlyendochondral ossification and mechanical strength in fracture healing。Life Sciences 80(2007)893—900.
[14]Rotter& Menshykova M,Winkler T’et a1.2008.Erythropoi·etin improves functional andhistological recovery of trauma-tized skeletal muscle tissue.J Orthop Res 26:1 6 1 8—1 626.
[15]Maiese K,Li F’Chong ZZ.2005.New avenues of exploration for erythropoietin.JAMA293:90—95.
[16]Walden AP,Young JD,Sharpies E.2010.Bench to bedside:a role for erythropoietin insepsis.2010;14(4):227.
EFFECT OF Erythropoietin INJECTION ON EARLY HEALING OF Achilles TENDON RUPTURE IN
Li yong ye hai xia zhangjianxin .
Department of Trauma and Orthopaedics, Qingtian people’s hospital, lishui zhejiang, 323900, P.R.China.
Objective Erythropoietin (EPO) can promote wound healing. To observe the effect ofEPO injection on the early healing of white rabbit’s Achilles tendon rupture so as to provide the experimental basis for clinicalpractice. Methods Forty-six Sprague Dawley white rabbits were included in this experiment, female or male and weighing 190-240 g. EPO and platelet-poor plasma (PPP) were prepared from the heart arterial blood of 10 rats; other 36 rats were made themodels of Achilles tendon rupture, and were randomly divided into 3 groups (control group, PPP group, and PRP group),12 rats for each group. In PPP and PRP groups, PPP and PRP of 100 μL were injected around the tendons once a week,respectively; in the control group, nothing was injected. The tendon tissue sample was harvested at 1, 2, 3, and 4 weeks afteroperation for morphology, histology, and immunohistochemistry observations. The content of collagen type I fi bers also was measured. Specimens of each group were obtained for biomechanical test at 4 weeks. Results All the animals survived till the end of the experiment. Tendon edema gradually decreased and sliding improved with time. The tendon adhesion increasedsteadily from 1 week to 3 weeks postoperatively, and it was relieved at 4 weeks in 3 groups. There was no signifi cant diff erencein the grading of tendon adhesion among 3 groups at 1 week and at 4 weeks (P > 0.05), respectively. The infl ammatory cellinfi ltration, angiogenesis, and collagen fi bers were more in PRP group than in PPP group and control group at 1 week; withtime, infl ammatory cell infi ltration and angiogenesis gradually decreased.Positive staining of collagen type I fi bers was observedat 1-4 weeks postoperatively in 3 groups. The positive density of collagen type I fi bers in group EPO was signifi cantly higher thanthat in control group and PPP group at 1, 2, and 3 weeks (P < 0.05), but no signifi cant diff erence was found among 3 groups at4 weeks (P > 0.05). The biomechanical tests showed that there was no signifi cant diff erence in the maximal gliding excursionamong 3 groups at 4 weeks postoperatively (P > 0.05); the elasticity modulus and the ultimate tensile strength of EPO group weresignifi cantly higher than those of control group and PPP group at 4 weeks (P < 0.05). Conclusion EPO injection can improvethe healing of Achilles tendon in early repair of rat’s Achilles tendon rupture.
Rabbit Achilles tendon rupture early in the end of the injection of EPO can promote Achilles tendon healing